I prescribe a lot of taxol.
Here, in Canada, Bristol Meyers Squibb is pricing taxol (paclitaxel) very agressively, and just cut its' price by about 1/3. I expect that it will be cut further, to keep their market share. BMY is well known in the field of oncology.
For this reason, I don't think that a generic taxol maker/seller is going to waltz into the market, and push Bristol aside.
I might be wrong, however ( as a small Australian firm basically completely replaced Pharmacia-Upjohn whe Adriamycin went generic).
DG
Incidently, although I follow BIOX, I have sold all of my shares (ay too soon, unfortunately). It is very expensive, in my opinion, (as a product, that is), and where is the proof that it is any better than intraarticular cortisone ? Finally, there are alternatives up here in the frozen tundra, but they have been very poorly marketed, to date !! |
